Dr. Jaeyun Kim1,2, Dr. Dian R. Arifin1, Dr. Naser Muja1, Taeho Kim1,2, Dr. Assaf A. Gilad1, Dr. Heechul Kim1, Dr. Aravind Arepally1, Prof. Taeghwan Hyeon2, Prof. Jeff W. M. Bulte1
1Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, Institute for Cell Engineering, Cellular Imaging Section, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 (USA)
2National Creative Research Initiative Center for Oxide Nanocrystalline Materials, World Class University program of Chemical Convergence for Energy and Environment, School of Chemical and Biological Engineering, Seoul National University, Seoul 151-744 (South Korea)
†This work was supported by NIH RO1 EB007825 (J.W.M.B.), U54 CA151838 (J.W.M.B.), and the Maryland TEDCO Nanotechnology Fund (J.W.M.B.), and National Creative Research Initiative grant R16-2002-003-01001-0 (T.H.), Strategic Research grant 2010-0029138 (T.H.), and World Class University Program R31-10013 (T.H.) of the National Research Foundation (NRF) of Korea. Human islets were provided by the National Islet Cell Resource Center. J.W.M.B is a paid consultant for Surgivision, Inc. This arrangement has been approved by The Johns Hopkins University in accordance with its Conflict of Interest policies.
The separate encapsulation of nanoparticles (NPs) and pancreatic islets in an alginate capsule-in-capsule (CIC) structure prevents the nanoparticles being toxic to the cells while housing a high payload of nanoparticles for imaging purposes (see picture). The CIC-encapsulated islets showed an improved insulin secretion over cells encapsulated in single capsules and their transplantation into diabetic mice restored normal glycemia.
Keywords: capsules;cell delivery;imaging agents;insulin;nanostructures